Last reviewed · How we verify
Omalizumab (CinnaGen)
Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing its interaction with high-affinity IgE receptors on mast cells and basophils.
Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing its interaction with high-affinity IgE receptors on mast cells and basophils. Used for Moderate to severe allergic asthma, Chronic idiopathic urticaria, Nasal polyposis.
At a glance
| Generic name | Omalizumab (CinnaGen) |
|---|---|
| Also known as | Zerafil® |
| Sponsor | Cinnagen |
| Drug class | IgE monoclonal antibody |
| Target | Immunoglobulin E (IgE) |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
By sequestering free IgE, omalizumab reduces the activation of mast cells and basophils that would otherwise occur upon allergen exposure. This suppression of the allergic cascade reduces the release of inflammatory mediators such as histamine, tryptase, and cytokines, thereby decreasing allergic symptoms and airway hyperresponsiveness in allergic asthma and other IgE-mediated conditions.
Approved indications
- Moderate to severe allergic asthma
- Chronic idiopathic urticaria
- Nasal polyposis
Common side effects
- Injection site reaction
- Headache
- Upper respiratory tract infection
- Arthralgia
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omalizumab (CinnaGen) CI brief — competitive landscape report
- Omalizumab (CinnaGen) updates RSS · CI watch RSS
- Cinnagen portfolio CI